

Ref. No: 1077
Date: 15/07/24
Subject: Oncology Supplemental

REQUEST

Q1. Do you treat patients for Urothelial cancer (Yes or No)? If No, where do you refer patients for treatment

Q2. How many patients were treated for Urothelial cancer (any stage) in the past 3 months with the following treatments:

- Atezolizumab (Tecentriq)
- Avelumab (Bavencio)
- Carboplatin single agent or in any other combination
- Carboplatin with Gemcitabine
- Carboplatin with Paclitaxel
- Cisplatin single agent or in any other combination
- Cisplatin with Gemcitabine
- Cisplatin with Gemcitabine + Nivolumab (Opdivo)
- Enfortumab Vedotin + Pembrolizumab (Padcev + Keytruda)
- Nivolumab (Opdivo)
- Pembrolizumab (Keytruda)
- Other active systemic anti-cancer therapy
- Palliative care only

Q3. Does your trust participate in any ongoing clinical trials for the treatment of urothelial cancer? If so, can you please provide the name of each trial along with the number of patients taking part?

RESPONSE

St Helens and Knowsley Teaching Hospitals NHS Trust and Southport and Ormskirk Hospital NHS Trust became a single legal entity known as Mersey and West Lancashire Teaching Hospitals NHS Trust on 1st July 2023, as such parts of the response may be provided in two sections relating to the hospital sites of each of the legacy organisations.

Q1. Do you treat patients for Urothelial cancer (Yes or No)? If No, where do you refer patients for treatment

Q2. How many patients were treated for Urothelial cancer (any stage) in the past 3 months with the following treatments:

- **Atezolizumab (Tecentriq)**
- **Avelumab (Bavencio)**
- **Carboplatin single agent or in any other combination**
- **Carboplatin with Gemcitabine**
- **Carboplatin with Paclitaxel**
- **Cisplatin single agent or in any other combination**
- **Cisplatin with Gemcitabine**
- **Cisplatin with Gemcitabine + Nivolumab (Opdivo)**
- **Enfortumab Vedotin + Pembrolizumab (Padcev + Keytruda)**
- **Nivolumab (Opdivo)**
- **Pembrolizumab (Keytruda)**
- **Other active systemic anti-cancer therapy**
- **Palliative care only**

Q3. Does your trust participate in any ongoing clinical trials for the treatment of urothelial cancer? If so, can you please provide the name of each trial along with the number of patients taking part?

These treatment modalities are owned by Clatterbridge and not MWL.

Please refer your request to: <https://www.wuth.nhs.uk/our-locations/clatterbridge-hospital/>